Agent Orange

Agent Orange information from Vietnam Veterans of America (VVA)

Information on Agent Orange and VA Benefits (VA)

Self-Help Guide to Service-Connected Disability Compensation For Exposure To Agent Orange for Veterans and Their Families (VVA)

Blue Water Navy.  “The Blue Water Navy Vietnam Veterans Act of 2019 (P.L. 116-23) is the most recent action taken by Congress to grant disability compensation benefits to veterans exposed to Agent Orange, a combination of tactical herbicides used by the U.S. military in Vietnam. Earlier legislation directed the Department of Veterans Affairs (VA) to provide some veterans with VA benefits for specific disabilities without requiring proof of actual exposure to Agent Orange. …The act requires VA to grant the presumption of exposure to herbicide agents to veterans who served on U.S. Navy or Coast Guard vessels off the coast of Vietnam.”  FOR MORE DETAILS SEE: Expansion of Benefits to Blue Water Navy Vietnam Veterans, Congressional Research Service, Report IF11368, November 20, 2019.


Presumptive conditions for VA service-connection claims:

Presumptive Condition: Authorized by:
Adult fibrosarcoma 38 CFR § 3.309(e)
AL amyloidosis 38 CFR § 3.309(e)
Alveolar soft part sarcoma 38 CFR § 3.309(e)
Angiosarcoma (hemangiosarcoma and lymphangiosarcoma) 38 CFR § 3.309(e)
B-cell leukemias, chronic (all, including, but not limited to, hairy-cell leukemia and chronic lymphocytic leukemia) 38 CFR § 3.309(e)
Bladder cancer 38 USC 1116(a)(2)
Chloracne or another acneform disease consistent with chloracne becoming manifest to a degree of disability of 10 percent or more within one year after the last date on which the veteran performed active military, naval, or air service in the Republic of Vietnam during the period beginning on January 9, 1962, and ending on May 7, 1975 38 USC 1116(a)(2);
38 CFR § 3.309(e)
Clear cell sarcoma of tendons and aponeuroses 38 CFR § 3.309(e)
Congenital and infantile fibrosarcoma 38 CFR § 3.309(e)
Dermatofibrosarcoma protuberans 38 CFR § 3.309(e)
Diabetes Mellitus (Type 2) 38 USC 1116(a)(2)
Diabetes, Type 2 (also known as Type II diabetes mellitus or adult-onset diabetes) 38 CFR § 3.309(e)
Early-onset peripheral neuropathy 38 CFR § 3.309(e)
Ectomesenchymoma 38 CFR § 3.309(e)
Epithelioid leiomyosarcoma (malignant leiomyoblastoma) 38 CFR § 3.309(e)
Epithelioid sarcoma 38 CFR § 3.309(e)
Extraskeletal Ewing’s sarcoma 38 CFR § 3.309(e)
Hodgkin’s disease becoming manifest to a degree of disability of 10 percent or more 38 USC 1116(a)(2);
38 CFR § 3.309(e)
Hypothyroidism 38 USC 1116(a)(2)
Ischemic heart disease (including, but not limited to, acute, subacute, and old myocardial infarction; atherosclerotic cardiovascular disease including coronary artery disease (including coronary spasm) and coronary bypass surgery; and stable, unstable and Prinzmetal’s angina) 38 CFR § 3.309(e)
Leiomyosarcoma 38 CFR § 3.309(e)
Liposarcoma 38 CFR § 3.309(e)
Malignant fibrous histiocytoma 38 CFR § 3.309(e)
Malignant ganglioneuroma 38 CFR § 3.309(e)
Malignant giant cell tumor of tendon sheath 38 CFR § 3.309(e)
Malignant glomus tumor 38 CFR § 3.309(e)
Malignant granular cell tumor 38 CFR § 3.309(e)
Malignant hemangiopericytoma 38 CFR § 3.309(e)
Malignant mesenchymoma 38 CFR § 3.309(e)
Malignant schwannoma, including malignant schwannoma with rhabdomyoblastic differentiation (malignant Triton tumor), glandular and epithelioid malignant schwannomas 38 CFR § 3.309(e)
Multiple myeloma becoming manifest to a degree of disability of 10 percent or more 38 USC 1116(a)(2);
38 CFR § 3.309(e)
Non-Hodgkin’s lymphoma becoming manifest to a degree of disability of 10 percent or more. 38 USC 1116(a)(2);
38 CFR § 3.309(e)
Parkinson’s disease 38 CFR § 3.309(e)
Parkinsonism 38 USC 1116(a)(2)
Porphyria cutanea tarda becoming manifest to a degree of disability of 10 percent or more within a year after the last date on which the veteran performed active military, naval, or air service in the Republic of Vietnam during the period beginning on January 9, 1962, and ending on May 7, 1975 38 USC 1116(a)(2);
38 CFR § 3.309(e)
Proliferating (systemic) angioendotheliomatosis 38 CFR § 3.309(e)
Prostate cancer 38 CFR § 3.309(e)
Respiratory cancers (cancer of the lung, bronchus, larynx, or trachea) becoming manifest to a degree of disability of 10 percent or more 38 CFR § 3.309(e)
Rhabdomyosarcoma 38 CFR § 3.309(e)
Soft-tissue sarcoma 38 USC 1116(a)(2)
soft-tissue sarcoma becoming manifest to a degree of disability of 10 percent or more other than osteosarcoma, chondrosarcoma, Kaposi’s sarcoma, or mesothelioma 38 CFR § 3.309(e)
Synovial sarcoma (malignant synovioma) 38 CFR § 3.309(e)